All In MedTech

FDA Clearance Tracker · P240039-S001

SetPoint System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P240039-S001
Device name
SetPoint System
Applicant location
Valencia, CA
Received
Aug 27, 2025
Decided
Jan 16, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P240039

Device type

Device class
Class III

Every decision under product code SFJ

FDA's approval statement

As written in FDA's record.

The SetPoint System is indicated for use in the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response, loss of response, or intolerance to one or more biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs).

Source documents

Other decisions for SetPoint Medical

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.